Key points: Duvelisib significantly improved progression-free survival and overall response rates compared with ofatumumab in relapsed or refractory chronic lymphocytic leukemia patients. Duvelisib
Home / Resource Library / The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL